While anti-PD-1 therapy can be effective in patients with breast cancer, response varies and is often limited by the development of resistance. Here, the authors investigate molecular determinant of response and resistance using multiomic single nucleus sequencing of longitudinal biopsies taken from breast cancer patients on a phase II clinical trial investigating neoadjuvant chemotherapy and pembrolizumab (anti-PD-1).
- Jingxin Fu
- Adrienne G. Waks
- Eliezer M. Van Allen
